yahoo_financeOriginal article
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
Patent ExpiryKeytrudaNeutral
AI Analysis
Summary
Retail traders are speculating on potential biotech acquisition targets for Merck as Keytruda faces a significant $31.7B patent cliff. The article discusses market speculation around Selecta Biosciences and Miltex as possible acquisition candidates.
Financial Highlights
Revenue
$31.7B
Outcome Details
Keytruda patent cliff approaching with $31.7B at risk
Importance:5/10
Sentiment:
0.00
M&Apatent_cliffacquisitionbiotech
Read the original article
Published by yahoo_finance on July 13, 2026 2:48 AM